Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCSK9 | Q8NBP7 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 10/20 | 0.51 |
| ▸ | NPC1 | O15118 | 9/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | ACP1 | P24666 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11451768 | 0.81 | ELANE (0.61) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL2541597 | 0.80 | NPC1 (0.53) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL19935958 | 0.80 | LATS1 (0.47) | PCSK9RAB9ANPC1ALDH1A1TP53 | |
| SCHEMBL18013087 | 0.78 | ELANE (0.63) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL3953148 | 0.77 | ELANE (0.61) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL5021496 | 0.77 | PCSK9 (0.59) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL4816936 | 0.77 | NPC1 (0.51) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL7540148 | 0.75 | NPC1 (0.50) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL18013092 | 0.75 | ELANE (0.65) | PCSK9RAB9ANPC1SMN1; SMN2PKM | |
| SCHEMBL18013093 | 0.75 | ELANE (0.65) | PCSK9RAB9ANPC1SMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2021-07-29 | — | — | US | disclosed |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2019-07-11 | — | — | US | disclosed |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | ABEL-SANTOS ERNESTO (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016127102-A2 | INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS | ABEL-SANTOS ERNESTO (US) | 2016-08-11 | — | — | WO | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| WO-2009029617-A1 | DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | CASP3, SI, PYCARD | PCSK9 667/4885RAB9A 4497/4885NPC1 1750/4885 |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | PCSK9 667/4885RAB9A 4497/4885NPC1 1750/4885 |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | PCSK9 667/4885RAB9A 4497/4885NPC1 1750/4885 |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | PCSK9 667/4885RAB9A 4497/4885NPC1 1750/4885 |
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | PCSK9 1451/4885RAB9A 1527/4885NPC1 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.